Koc-Kan Ho
Overview
Explore the profile of Koc-Kan Ho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
246
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng J, Yang H, Haak V, Yang J, Kipper F, Barksdale C, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(41).
PMID: 34607951
Cancer therapy reduces tumor burden via tumor cell death ("debris"), which can accelerate tumor progression via the failure of inflammation resolution. Thus, there is an urgent need to develop treatment...
2.
Xu Y, Brenning B, Kultgen S, Foulks J, Clifford A, Lai S, et al.
ACS Med Chem Lett
. 2015 Jan;
6(1):63-7.
PMID: 25589932
Pim-1 has emerged as an attractive target for developing therapeutic agents for treating disorders involving abnormal cell growth, especially cancers. Herein we present lead optimization, chemical synthesis and biological evaluation...
3.
Foulks J, Carpenter K, Luo B, Xu Y, Senina A, Nix R, et al.
Neoplasia
. 2014 Jun;
16(5):403-12.
PMID: 24953177
The proto-oncogene proviral integration site for moloney murine leukemia virus (PIM) kinases (PIM-1, PIM-2, and PIM-3) are serine/threonine kinases that are involved in a number of signaling pathways important to...
4.
Xu Y, Liu X, Saunders M, Pearce S, Foulks J, Parnell K, et al.
Bioorg Med Chem Lett
. 2013 Dec;
24(2):515-9.
PMID: 24374270
Activators of the pyruvate kinase M2 (PKM2) are currently attracting significant interest as potential anticancer therapies. They may achieve a novel antiproliferation response in cancer cells through modulation of the...
5.
Xu Y, Foulks J, Clifford A, Brenning B, Lai S, Luo B, et al.
Bioorg Med Chem Lett
. 2013 Jun;
23(14):4072-5.
PMID: 23756368
2-Arylamino-4-aryl-pyrimidines were found to be potent inhibitors of PAK1 kinase. The synthesis and SAR are described. The incorporation of a bromide at the 5-position of the pyrimidine core and in...
6.
Parnell K, Foulks J, Nix R, Clifford A, Bullough J, Luo B, et al.
Mol Cancer Ther
. 2013 May;
12(8):1453-60.
PMID: 23720766
Inactivation of the M2 form of pyruvate kinase (PKM2) in cancer cells is associated with increased tumorigenicity. To test the hypothesis that tumor growth may be inhibited through the PKM2...
7.
Ho K, Parnell K, Yuan Y, Xu Y, Kultgen S, Hamblin S, et al.
Bioorg Med Chem Lett
. 2012 Dec;
23(2):569-73.
PMID: 23232060
A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described. These compounds were used as tools...
8.
Foulks J, Parnell K, Nix R, Chau S, Swierczek K, Saunders M, et al.
J Biomol Screen
. 2011 Oct;
17(1):2-17.
PMID: 21965114
Epigenetic modification of DNA leads to changes in gene expression. DNA methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the methylation of CpG dinucleotides, resulting in an epigenetic...
9.
Ratcliffe P, Abernethy L, Ansari N, Cameron K, Clarkson T, Dempster M, et al.
Bioorg Med Chem Lett
. 2011 Jul;
21(15):4652-7.
PMID: 21723725
Systematic optimisation of a poorly soluble lead series of isoxazole-3-carboxamides was conducted. Substitution of the 4-position with specific polar functionality afforded the requisite balance of potency, solubility and physicochemical properties....
10.
Napier S, Letourneau J, Ansari N, Auld D, Baker J, Best S, et al.
Bioorg Med Chem Lett
. 2011 May;
21(12):3813-7.
PMID: 21596563
Synthesis and structure-activity relationships (SAR) of a novel series of vasopressin V(1b) antagonists are described. 2-(6-Aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide have been identified with low nanomolar affinity for the V(1b) receptor and good selectivity...